CytoSorbents Q2 FY26 operating loss narrows 27% to $2.6 million; revenue rises 0.2% to $9.6 million

Reuters2026/08/06 21:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CytoSorbents posted a GAAP net loss of $4.42 million for Q2, swinging from net income of $1.95 million a year earlier.
Revenue was $9.63 million, up 0.2% year over year; gross margin rose 2.3 percentage points to 73.2%.
Operating loss narrowed 27% to $2.64 million, while operating cash burn fell to $0.4 million from $1.4 million a year earlier.
DrugSorb-ATR STAR-T pivotal trial results were published in the Journal of Thoracic and Cardiovascular Surgery, concluding ticagrelor removal was safe and reduced bleeding severity.
Expects operating cash flow break-even in the second half of 2026; targets a new DrugSorb-ATR De Novo submission in early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-092006), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CytoSorbents Q2 FY26 operating loss narrows 27% to $2.6 million; revenue rises 0.2% to $9.6 million

You may also like

Crypto prices